Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Level Bio ABFRA:4MB -12.50%23 Equity-to-Asset is 0.04 as of Mar. 2026, which is 89% below its 10-year median of 0.37. GuruFocus rates FRA:4MB with a GF Score™ of 23/100. The stock has 4 warning signs investors should review. Among 210 Medical Diagnostics & Research companies, Level Bio AB ranks worse than 90.48% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Level Bio AB's Total Stockholders Equity for the quarter that ended in Mar. 2026 was €0.04 Mil. Level Bio AB's Total Assets for the quarter that ended in Mar. 2026 was €1.22 Mil.
Therefore, Level Bio AB's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.04.
The historical rank and industry rank for Level Bio AB's Equity-to-Asset or its related term are showing as below:
FRA:4MB'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.04 Med: 0.37 Max: 0.76
Current: 0.04
During the past 13 years, the highest Equity to Asset Ratio of Level Bio AB was 0.76. The lowest was 0.04. And the median was 0.37.
FRA:4MB's Equity-to-Asset is ranked worse than 90.48% of 210
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.59
vs FRA:4MB: 0.04
Level Bio AB (FRA:4MB) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Level Bio AB Equity-to-Asset Related Terms
Level Bio AB Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Level Bio AB's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4MB vs TMO, DHR, IDXX: Equity-to-Asset Comparison
For the Diagnostics & Research subindustry, Level Bio AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Level Bio AB Equity-to-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Level Bio AB's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Level Bio AB's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Level Bio AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Level Bio AB (FRA:4MB) has a Equity-to-Asset of 0.04 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Level Bio AB and its competitors. This is 89% below median its historical median of 0.37. Over the past decade, Level Bio AB's Equity-to-Asset has ranged from 0.04 to 0.76. According to the industry distribution chart, Level Bio AB ranks #190 out of 210 companies in the Medical Diagnostics & Research industry, placing it in the top 90.5%.
Is Level Bio AB's Equity-to-Asset too high?
Level Bio AB's current Equity-to-Asset of 0.04 is 89% below median its 10-year median of 0.37. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 0.76. The Medical Diagnostics & Research industry median Equity-to-Asset is 0.59. Level Bio AB's value of 0.04 is 93.2% below this industry median. Based on the distribution chart, Level Bio AB ranks #190 out of 210 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Level Bio AB has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Level Bio AB's Equity-to-Asset compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Level Bio AB ranks #190 out of 210 companies for Equity-to-Asset. This places Level Bio AB in the lower half of its industry. The industry median Equity-to-Asset is 0.59. Level Bio AB's value of 0.04 is 93.2% below this benchmark. Historically, Level Bio AB's own Equity-to-Asset has ranged from 0.04 to 0.76 over the past decade. While the company's 10-year median is 0.37 vs. the industry median of 0.59, Level Bio AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Diagnostics & Research company?
The median Equity-to-Asset among Medical Diagnostics & Research companies is 0.59, based on 210 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Level Bio AB's current Equity-to-Asset of 0.04 is 93.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Level Bio AB and its competitors. For the Medical Diagnostics & Research industry, the median Equity-to-Asset is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Level Bio AB's current Equity-to-Asset is 0.04, which is 89% below median its own 10-year median of 0.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Level Bio AB stock overvalued right now?
Level Bio AB (FRA:4MB) has a current Equity-to-Asset of 0.04. The current Equity-to-Asset is 0.04, which is 89% below median its 10-year median of 0.37 and 93.2% below the Medical Diagnostics & Research industry median of 0.59. Level Bio AB's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Level Bio AB (FRA:4MB), the current Equity-to-Asset is 0.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Level Bio AB is a parent company and operates through subsidiary. It develops and manufactures diagnostic kits for the clinical market and also is a distributor and full service partner to molecular biology labs in the Nordics.
23GF Score
Get the complete analysis for FRA:4MB
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4MB has been successfully added to your 
